A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Depression, Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 5/30/2018 |
| Start Date: | May 22, 2017 |
| End Date: | March 14, 2018 |
A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-911 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical
study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of
SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the
safety, tolerability, and pharmacokinetic profile.
study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of
SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the
safety, tolerability, and pharmacokinetic profile.
This is a single and multiple ascending dose study to assess the safety, tolerability and
pharmacokinetics of SUVN-911 administered orally once a day to healthy male subjects. The
study will be conducted under double-blind conditions.
The primary objectives are to evaluate the safety and tolerability of SUVN-911 following oral
administration of single or multiple ascending doses and estimate the maximum tolerated dose
of SUVN-911, if possible.
The secondary objectives are to evaluate the single and repeat dose plasma and urine
pharmacokinetics of SUVN-911 following oral administration of single and multiple ascending
doses in healthy male subjects.
pharmacokinetics of SUVN-911 administered orally once a day to healthy male subjects. The
study will be conducted under double-blind conditions.
The primary objectives are to evaluate the safety and tolerability of SUVN-911 following oral
administration of single or multiple ascending doses and estimate the maximum tolerated dose
of SUVN-911, if possible.
The secondary objectives are to evaluate the single and repeat dose plasma and urine
pharmacokinetics of SUVN-911 following oral administration of single and multiple ascending
doses in healthy male subjects.
Inclusion Criteria:
- Healthy male aged 18 to 45 years with a body mass index (BMI) between 18 and 30 kg/m2,
(inclusive).
Exclusion Criteria:
- Standard exclusion criterion for Phase 1 clinical trial in healthy subjects:
- History of any clinically significant disease or disorder which, in the opinion
of the Investigator, may either put the volunteer at risk because of
participation in the study, or influence the results or the volunteer's ability
to participate.
- History or presence of gastro intestinal (GI), hepatic, or renal disease or any
other condition known to interfere with absorption, distribution, metabolism, or
excretion of drugs as judged by Investigator.
We found this trial at
1
site
Click here to add this to my saved trials
